Below is an important message from one of our highly valued sponsors. Please read it carefully as they have some special information to share with you.
Dear Reader,
Almost no one sees it coming…
But AI is about to split America into two over the next 12 months…
On one hand, it'll make America's one-percenters richer and more powerful than ever…
But on the other hand, it's set to trap millions of hardworking Americans in financial quicksand…
So much so that former Google exec Kai-Fu Lee says AI could wipe out 50% of jobs by 2027…
Elon Musk has said AI will surpass human intelligence by 2027…
And Mark Zuckerberg has said half of all coding could be done by AI within the next year…
One ex-hedge fund manager whose team predicted NVIDIA's rise in 2020 calls this the "AI End Game"...
And he says there are three critical moves every American should make in the next 12 months to protect and grow their wealth through this paradigm shift…
CLICK HERE TO SEE THE DETAILS BEFORE IT'S TOO LATE
Regards,
Matt Insley
Publisher, Paradigm Press
5 Hot Buys Ready to Spring Higher in March
Author: Thomas Hughes. Published: 2/27/2026.
Key Points
- Five stocks have near-term March catalysts, with upside setups ranging from large-cap AI to early-stage photonics.
- Analyst targets and technical levels point to further gains, but volatility varies widely across the list.
- The mix spans AI compute/memory, batteries, consumer beauty, and data-center cooling.
- Special Report: [Sponsorship-Ad-6-Format3]
Spring is about to arrive, and with it come several hot buys for traders and investors. Questions include what drives the market, which catalysts are at hand, and how high shares could go.
In each case, bull-case scenarios suggest modest to moderate triple-digit gains are possible over time. The practical question for investors and traders is which names fit a portfolio and how many shares to buy.
Advanced Micro Devices Advancing Toward Critical Catalyst
Elon Musk: This Could Turn $100 into $100,000 (Ad)
What if you could shrink your entire wealth journey from decades down to just 24 hours?
Sounds impossible…
But I'll show you how Elon Musk is about to make it a reality.
The Advanced Micro Devices (NASDAQ: AMD) outlook is supported by end-market normalization in key segments. AI and data centers are driving company revenue to record levels and accelerating growth.
Key 2025 catalysts include very strong GPU and CPU demand tied to AI and datacenter build-outs, along with the upcoming launch of MI450 products and Helios rack-scale solutions. Rack-scale solutions in particular could help AMD close the gap with NVIDIA (NASDAQ: NVDA) and better serve hyperscaler needs.
In February, analysts revised price targets and issued upgrades, reaffirming a Moderate Buy rating and highlighting roughly 45% upside from key support levels. High-end targets — which could be reached by year-end if trends persist — imply about 90% upside. If upcoming results match industry strength, both consensus and high-end targets are likely to move higher.
Micron Technology Signals Continuation of Trend
Micron Technology (NASDAQ: MU) benefits from the same AI-driven tailwinds as AMD, but its price action is tied to its role as a high-bandwidth memory (HBM) provider, a critical component for AI applications worldwide.
In late February, MU broke out of a consolidation, signaling a continuation of the uptrend. That breakout marks roughly the halfway point of this rally: the stock has already advanced about $200 (roughly 100%) since the last major correction. In this scenario, MU could move into the $600–$800 range by year-end, possibly sooner.
As of month-end, consensus price targets lagged the recent action, but they still support the trend: analysts have increased coverage, the consensus target has risen nearly 200% over the trailing 12 months, and the high-end target points to $500.
Amprius Technologies: Earnings Ramp Underway
Amprius Technologies (NYSE: AMPX) is positioned as a potentially disruptive force in the battery market. Its silicon anode design offers superior energy density and performance, which matter for range and payload capacity.
In February, the upcoming March earnings release emerged as a likely catalyst that could confirm the company's growth trajectory. Analysts forecast high-double to low-triple-digit revenue growth over the next eight quarters, with profitability expected by the end of 2027.
Technically, AMPX is set up to channel toward the top of its range and could top $15 before mid-year. Consensus targets above $16.50 would represent roughly 75% upside from critical support levels.
e.l.f. Beauty Is at a Buyable Bottom
e.l.f. Beauty (NYSE: ELF) appears to be in a turnaround driven by operational execution, market-share gains and a stronger growth outlook. The stock confirmed a bottom in February after the earnings release and now looks buyable.
The company provided an aggressive 2026 guide, with revenue and earnings growth coming in well above expectations at the low end of the range. Analysts' reactions were mixed, including a few price-target reductions, but overall the takeaway is constructive: consensus still points to nearly 30% upside.
A 30% move would push shares above key moving averages and set the stock up to advance through the year. Over the longer term, valuation metrics and the earnings outlook suggest the stock could double as profitability and growth accelerate.
Aeluma: Betting Big on Keeping Data Centers Cool
Aeluma (NASDAQ: ALMU) is the riskiest pick on this list because it is still pre-revenue. It is, however, on track to commercialize its technology by year-end, and early demand appears strong.
The company develops highly efficient photonic processes and manufacturing techniques for compound semiconductors. Photonics enable higher-speed, lower-latency, high-bandwidth data transmission — capabilities that matter for the most advanced AI applications and for cooling and interconnect solutions in data centers.
Analysts rate ALMU as a Hold with a consensus that implies about 65% upside. Catalysts this year include new U.S. government contracts and the expectation of follow-on work as deployments progress. Reaching consensus would put shares back at their all-time high and position the company for continued advancement in the years ahead.
Boring Is Beautiful: Why Johnson & Johnson Is Beating the Tech Sector
Reported by Jeffrey Neal Johnson. First Published: 2/24/2026.
Key Points
- Johnson & Johnson has maintained an impressive streak of increasing its dividend payouts for generations, rewarding long-term shareholders with reliable income.
- Management is driving future expansion by focusing on high-growth pharmaceutical assets and cutting-edge medical technologies, such as robotics.
- Investors looking for shelter from market volatility benefit from a stock that historically moves much less than the broader market indices.
- Special Report: [Sponsorship-Ad-6-Format3]
While the technology sector faces renewed volatility driven by artificial intelligence (AI) scare trades and valuation concerns, a different story is playing out in the healthcare sector. Investors fleeing the jittery price swings of high-growth tech stocks are finding shelter in a familiar name that is quietly outperforming. Johnson & Johnson (NYSE: JNJ) is trading near all-time highs of about $245 per share, creating a divergence that has caught Wall Street's attention.
This rally challenges the perception of the healthcare giant as a slow-moving, "boring" stock. Over the last 30 days, shares have climbed roughly 14%, significantly outperforming the broader market during a period of uncertainty. That price action suggests institutional money is rotating out of riskier assets and placing a premium on stability, reliable cash flow, and consistent execution.
Have $500? Invest in Elon's AI Masterplan (Ad)
What if you could claim a stake in what's set to be the biggest IPO ever… starting with just $500?
Everyone is talking about Elon Musk's SpaceX IPO.
For investors watching the ticker on Feb. 24, 2026, note a specific calendar event: today is the ex-dividend date for Johnson & Johnson. The stock price will likely decline by the upcoming dividend amount, $1.30 per share — a mechanical adjustment rather than a reflection of business performance. For income-focused investors, that technical dip often presents an attractive entry point rather than a reason to sell.
64 Years of Unbroken Growth
The primary argument for holding Johnson & Johnson during turbulent market cycles is its financial stability and role as a portfolio stabilizer. The company belongs to an elite group of equities known as Dividend Kings, firms that have increased their dividend for at least 50 consecutive years.
Johnson & Johnson has now raised its dividend for 64 consecutive years, a track record that spans recessions, market crashes, and geopolitical shocks. That reliability is rare in a market focused on speculative growth.
Currently, the stock yields about 2.12% on an annual payout of $5.20 per share. While higher yields exist in fixed income or riskier sectors, J&J's appeal is the combination of yield, growth, and safety. Management projects free cash flow near $21 billion in 2026 — a large liquidity cushion that supports dividends, R&D investment, and legal expenses without heavy borrowing.
For risk-averse investors, one compelling metric is the stock's Beta. Beta measures how much a stock moves relative to the overall market (S&P 500). A Beta of 1.0 moves in lockstep with the market; Johnson & Johnson's Beta is about 0.35, meaning it has historically been roughly 65% less volatile than the broader market. When tech stocks swing wildly, J&J tends to hold its ground. Adding JNJ to a tech-heavy portfolio can act as a mathematical shock absorber, dampening overall volatility while preserving equity exposure.
Beyond the Patent Cliff: The Road to $100 Billion
A common misconception about safe stocks is that they cannot grow. Johnson & Johnson is disproving that with a strategic pivot that is paying off. Management has issued strong guidance for 2026, projecting full-year revenue to surpass $100 billion for the first time in company history and forecasting adjusted earnings per share (EPS) of about $11.53.
This growth is driven by a reinvigorated pharmaceutical division, now branded as Innovative Medicine. Investors worried about the patent cliff after Stelara lost exclusivity in 2025 have seen that J&J can absorb declines through the rise of new blockbusters.
Two key assets are driving this resilience:
- Darzalex: An oncology mainstay generating roughly $14 billion in annual sales, cementing J&J's leadership in multiple myeloma treatment.
- Tremfya: Positioned as a successor to Stelara, Tremfya released strong three-year remission data for ulcerative colitis, helping the company retain market share in immunology despite increased competition.
The Tech in MedTech: High-Margin Technologies
Growth extends beyond pharmaceuticals into the MedTech segment, which has shifted toward high-growth, higher-margin technologies. The integration of Shockwave Medical modernized J&J's cardiovascular portfolio.
Shockwave's intravascular lithotripsy (IVL) uses sonic pressure waves to break up calcified plaque in arteries — a significant improvement over traditional angioplasty balloons. By owning this technology, Johnson & Johnson gained a high-growth asset that complements its existing heart pump (Abiomed) and surgical offerings.
The company is also advancing in robotics. The submission of its Ottava robotic surgical system for FDA approval signals an intent to compete in the expanding soft-tissue robotics market. These high-tech devices tend to carry higher profit margins and create sticky relationships with hospital systems, providing a long-term earnings tailwind beyond commoditized products.
Addition by Subtraction: The Orthopedics Strategy
To sustain growth and improve margins, management is reshaping the corporate structure. One major development is exploring a sale — rather than a spin-off — of the DePuy Synthes orthopedics business.
Divesting orthopedics is an example of addition by subtraction. Orthopedics is a mature, lower-growth business compared with booming fields such as oncology and advanced cardiovascular devices. Shedding that unit could improve overall revenue growth and margins, and generate a large cash influx for acquisitions, share buybacks, or debt reduction.
Addressing legal risks is essential for a balanced view. J&J continues to face litigation over talc products, including a recent $1.5 billion verdict, and a new commercial lawsuit from Bayer over marketing claims for prostate cancer drugs adds noise to the news cycle.
However, the market's recent rally suggests investors are looking past these headlines. The consensus among bulls is that J&J's financial depth — more than $20 billion in cash and marketable securities, potential proceeds from an orthopedics sale, and roughly $21 billion in annual free cash flow — positions the company to manage liabilities without disrupting operations or the dividend. In other words, legal battles are treated as balance-sheet items rather than existential threats.
Capital Preservation With Upside
Johnson & Johnson has evolved from a slow-moving conglomerate into a focused, high-tech healthcare company. After shedding its consumer health division (Kenvue (NYSE: KVUE)) and potentially divesting orthopedics, management is concentrating on higher-growth opportunities in pharmaceuticals and medical technology.
Although the stock now trades near all-time highs and is no longer a bargain-bin value play, it offers a compelling mix of capital preservation and upside: a 64-year dividend growth streak, a low volatility profile, and a clear path to $100 billion in revenue. For investors fatigued by the unpredictability of the technology sector, Johnson & Johnson demonstrates that, in the current market environment, boring can be both beautiful and profitable.
This email content is a paid sponsorship provided by Paradigm Press, a third-party advertiser of DividendStocks.com and MarketBeat.
If you need assistance with your newsletter, please contact our South Dakota based support team at contact@marketbeat.com.
If you no longer wish to receive email from DividendStocks.com, you can unsubscribe.
Copyright 2006-2026 MarketBeat Media, LLC. All rights protected.
345 N Reid Pl., Sixth Floor, Sioux Falls, S.D. 57103. United States of America..